We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TTWO:NASDAQTake-Two Interactive Software, Inc. Analysis

Data as of 2026-06-25 - not real-time

$235.77

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Take‑Two is trading near its 20‑day and 50‑day moving averages with the price comfortably above the 200‑day average, suggesting a short‑term bias but a lack of strong longer‑term momentum. The RSI sits in the upper half of its range and the MACD histogram remains positive, reinforcing a bullish technical backdrop, while volume has been trending upward and the beta is comfortably below the market, indicating modest systematic risk. However, the stock is priced well above the discounted cash‑flow estimate and its forward P/E exceeds the industry average, flagging an overvalued condition despite a modest upside projection from the current price. Fundamentally, the company is generating solid operating cash flow and free cash flow, yet profitability is still negative and the debt‑to‑equity ratio is high, which tempers the enthusiasm from the cash generation story. Recent catalyst news—the launch of pre‑orders for Grand Theft Auto VI and a series of analyst upgrades with higher price targets—adds short‑term upside potential, but insider selling and a recent earnings beat that still left earnings per share negative highlight lingering execution concerns.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD and rising volume
  • Pre‑order launch for GTA VI driving immediate demand
  • Analyst upgrades and higher price objectives

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong franchise pipeline supporting revenue growth
  • High valuation relative to DCF and industry peers
  • Elevated debt levels limiting financial flexibility

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Long‑term cash‑flow generation from established IPs
  • Persistent overvaluation and negative profit margins
  • Potential for debt deleveraging as cash flow improves

Key Metrics & Analysis

Financial Health

Revenue Growth6.10%
Profit Margin-4.48%
P/E Ratio23.6
ROE-10.56%
ROA-0.53%
Debt/Equity84.26
P/B Ratio12.5
Op. Cash Flow$624.3M
Free Cash Flow$1.4B
Industry P/E16.2

Technical Analysis

TrendNeutral
RSI60.3
Support$206.00
Resistance$251.24
MA 20$222.35
MA 50$222.29
MA 200$230.87
MACDBullish
VolumeIncreasing
Fear & Greed Index89.46

Valuation

Fair Value$127.81
Target Price$281.11
Upside/Downside19.23%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.68
Volatility39.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.